Cookie Einstellungen

Zur Optimierung der Benutzerfreundlichkeit setzen wir Cookies ein. Wählen Sie aus, welche Cookies diese Webseite verwenden darf.  Datenschutzerklärung

Nur technisch erforderliche Cookies, die für die grundlegenden Funktionen unserer Webseite nötig sind, werden gesetzt.


Aptamers for Treatment and Diagnosis of Autoantibody-based dilated Cardiomyopathy

Reference Number TO 03-00302


Cardiovascular diseases still are a major cause of death despite the enormous efforts in cardiac therapy. Several factors may influence the onset and progression of the disease, and consequently, many forms of cardiovascular diseases can be observed. In approximately 70% of idiopathic dilated cardiomyopathy (DCM) patients and in nearly 100% of patients with Chagas’ cardiomyopathy and peripartum cardiomyopathy, antibodies to the beta1- adrenergic receptor are detected. With a prevalence of 36 cases per 100,000 people for idiopathic DCM, and a prevalence of 1000 cases per 100,000 people (Latin America) for Chagas’ cardiomyopathy, reliable means for auto-antibody diagnostics and cause-specific therapies are required.

Aptamers for Treatment and Diagnosis of Autoantibody-based dilated Cardiomyopathy

Decrease of human beta1-receptor auto-antibody induced heart beating rate through the antagonistic aptamers Apta 110 and 111 in a rat cardiomyocyte beating assay.


The technology relates to novel high-affinity aptamers specifically binding to auto-antibodies directed against the second extracellular loop of human beta1-adrenergic receptors. Due to the strong and specific binding, the aptamers can be used in a bioassay for antibody detection, enabling therapeutic decisions for depletion of pathogenic auto-antibodies by unspecific or specific immune aphaeresis. Furthermore, the aptamers have therapeutic potential for treatment of idiopatic DCM, Chagas’ cardiomyopathy and peripartum cardiomyopathy through selective inhibition of beta1-adrenergic auto-antibodies.

Commercial Opportunity

In-licensing and/or collaboration opportunity for development of a diagnostic tool or a novel therapeutic approach.

Patent Situation

PCT WO2012/000889 held by Charité – Universitätsmedizin Berlin, Max-Delbrück-Centrum für Molekulare Medizin, and Aptares AG is pending

Further Reading

Haberland et al., Circ. Res. 2011;109(9), 986-992